URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


2nd Chronic HBV Drug Development Summit


Date
Apr 25, 2022 - 08:00 AM - Apr 27, 04:00 PM
Organizer
Hanson Wade
Venue
Wyndham Boston Beacon Hill
Location
5 Blossom Street,

Boston,
MA,
US,
ZIP: 02114
Phone: +1 617 455 4188

Ticket Price: USD 2199.00 - USD 4846.00


With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms.

This industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. From dissecting safe induction of innate and adaptive immune pathways and elucidating the role of T-cells in clearing virus infections, to clinical progress in combination therapy and assessing durability of surface antigen seroclearance, don’t miss your chance to join the conversation.

Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress to achieve functional cure for chronic HBV.

Tickets    https://go.evvnt.com/966899-2?pid=1052
Brochure https://go.evvnt.com/966899-3?pid=1052

Prices:
Conference + Workshop Day - Drug Developer USD 3946.00
Conference Only - Drug Developer USD 2599.00
Conference + Workshop Day - Academic USD 3096.00
Conference Only - Academic USD 2199.00
Conference + Workshop Day - Service Provider USD 4846.00
Conference Only - Service Provider USD 3099.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development


Speaker Details


Alexander Ploss Associate Professor of Molecular Biology Princeton University, Andrew Vaillant Chief Scientific Officer Replicor, Bertrand Georges Chief Technology Officer Altimmune, Carey Hwang Senior Vice President, Clinical Research, Head of Chronic Infection Vir Biotechnology, Chari Cohen Senior Vice President Hepatitis B Foundation, David Anderson Chief Scientific Officer VBI Vaccines, Francisco Diaz- Mitoma Chief Medical Officer VBI Vaccines, Helmut Brunar Chief Executive Officer Viravaxx, Herbert Virgin Chief Scientific Officer & Executive Vice President of Research Vir Biotechnology, Hubert Trübel Chief Medical Officer AiCuris, Jeysen Yogaratnam Chief Medical Officer Drug Farm, Katie Kitrinos Vice President, Clinical Virology Assembly Biosciences, Kees Melief Chief Scientific Officer ISA Pharmaceuticals, Linong Zhang Director Sanofi Pasteur, Luisa Stamm Chief Medical Officer Assembly Biosciences, Mark Dybul Chief Executive Officer Enochian BioSciences, Martin Leivers Senior Director, Early Development Leader GSK, Michael Newman Founder & Chief Scientific Officer Indaptus Therapeutics, Nezam Afdhal Chief of the Division of Gastroenterology, Hepatology & Nutrition Beth Israel Deaconess Medical Center, Patricia Mendez Head HBV Cure Gilead Sciences, Patrick Kennedy Clinical Professor of Translational Hepatology Queen Mary University Of London, Rajan George Founder, President & Chief Executive Officer Akshaya Bio, Shihyun You Senior Scientific Director GSK, Thomas Baumert Professor of Medicine, Head Inserm Research Institute, Chair Hepatology University Hospital, Timothy Block President Hepatitis B Foundation

Event Categories
Keywords: hepatology, virology




Comments








Events Calendar

SunMonTueWedThuFriSat
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99